Page 45 - 北京京煤集团总医院第十一届·2023学术年会论文集

北京京煤集团总医院 第十一届·2023 学术年会论文集

fl oaters: a randomized clinical trial[J]. JAMA Ophthalmol, 2017, 135(9): 918-923.
[4] SINGH I P. Modern vitreolysis-YAG laser treatment now a real solution for the treatment of

symptomatic floaters[J]. Surv Ophthalmol, 2020, 65(5): 581-588.
[5] MILSTON R, MADIGAN M C, SEBAG J. Vitreous floaters: Etiology, diagnostics, and
management[J]. Surv Ophthalmol, 2016, 61(2): 211-227.
[6] GARCIA G A, KHOSHNEVIS M, YEE K M P, et al. The effects of aging vitreous on contrast

sensitivity function[J]. Graefes Arch Clin Exp Ophthalmol, 2018, 256(5): 919-925.
[7] KIM Y K, MOON S Y, YIM K M, et al. Psychological distress in patients with symptomatic
vitreous floaters[J]. J Ophthalmol, 2017(2017): 3191576.
[8] WAGLE A M, LIM W Y, YAP T P, et al. Utility values associated with vitreous fl oaters[J]. Am

J Ophthalmol, 2011, 152(1): 60-65.
[9] SU D, SHAH C P, HSU J. Laser vitreolysis for symptomatic floaters is not yet ready for
widespread adoption[J]. Surv Ophthalmol, 2020, 65(5): 589-591.
[10] KATSANOS A, TSALDARI N, GORGOLI K, et al. Safety and efficacy of YAG laser

vitreolysis for the treatment of vitreous fl oaters: an overview[J]. Adv Ther, 2020, 37(4): 1319-1327.
[11] 李静 谷威. UltraQ-YAG 玻璃体消融术治疗飞蚊症的临床初步观察[J]. 国际眼科杂志,

2016(16): 1369-1371.

（发表于《中国临床医生杂志》2023 年 51 卷 5 期 616 页）

- 41 -